From: Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia
Variable | n (%) | Median (IQR) |
---|---|---|
Age (years) | 62.8 (44.4–73.5) | |
Gender | ||
Male | 102 (54.0) | |
Female | 87 (46.0) | |
Baseline Comorbidities | ||
Heart Disease | 38 (20.1) | |
Peripheral vascular disease | 9 (4.8) | |
Cerebral vascular accident | 37 (19.6) | |
Chronic kidney disease | 28 (14.8) | |
End stage renal disease | 10 (5.3) | |
HIV | 1 (0.5) | |
Dementia | 19 (10.1) | |
COPD | 6 (3.2) | |
Connective tissue disease | 5 (2.7) | |
Peptic ulcer disease | 7 (3.7) | |
Mild liver disease | 7 (3.7) | |
Moderate and severe liver disease | 22 (11.6) | |
Diabetes Mellitus | 80 (42.3) | |
Non-hematological malignancy | 62 (32.8) | |
Hematological malignancy | 11 (5.8) | |
Solid organ transplant | 8 (4.2) | |
Bone marrow transplant | 4 (2.1) | |
Immunosuppressive medication | 41 (21.7) | |
Charlson comorbiditiy index | 6 (3–8) | |
APACHE II score1 | 19 (9.0–31.5) | |
Pitt bacteremia score2 | 2 (1–6) | |
Type of CRE infection3 | ||
CLABSI | 28 (14.8) | |
HAP/VAP | 45 (23.8) | |
Complicated UTI | 45 (23.8) | |
Complicated intra-abdominal infection | 32 (16.9) | |
Skin and soft tissue infection | 20 (10.6) | |
Joint/bone infection | 6 (3.2) | |
Primary bacteremia (source unidentified) | 15 (7.9) | |
Other | 19 (10.1) | |
Organism isolates4 | ||
Escherichia coli | 21 (11.1) | |
Klebsiella pneumoniae | 165 (87.3) | |
Both E. coli and K. pneumoniae | 2 (1.1) | |
CRE bacteremia | 77 (40.7) | |
Location at time of CRE culture | ||
Emergency Room | 20 (10.6) | |
Medical Floor | 52 (27.5) | |
Surgical Floor | 21 (11.1) | |
Hematology/Oncology Floor | 29 (15.3) | |
OB/GYN Floor | 1 (0.5) | |
ICU | 57 (30.2) | |
Other | 9 (4.8) | |
Molecular typing5 | ||
KPC | 1 (0.5) | |
NDM | 32 (16.9) | |
IMP | 1 (0.5) | |
OXA_48 | 131 (69.3) | |
None identified | 25 (13.2) |